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The Yale Chemical Biology Symposium is a day-long
event that highlights new advances at the interface of
chemistry and biology. Held annually since 1998, the
symposium features presentations by acclaimed in-
vestigators from academic and industrial institutions
as well as a poster session for student and postdoc-
toral presenters. The 2005 symposium held on May
13 featured Dr. Joshua Boger (Chairman, President,
and CEO of Vertex Pharmaceuticals, Inc.) as the key-
note speaker as well as Drs. Carolyn Bertozzi (UC
Berkeley), Alice Ting (MIT), Peter Lansbury (Harvard),
Patrick Loria (Yale), and Ronald Breaker (Yale). This
meeting review summarizes the novel chemical biol-
ogy approaches to fields as diverse as glycobiology,
neurochemistry, drug discovery, molecular biophys-
ics, and molecular genetics presented at the sym-
posium.
The immense complexity of biological systems often
demands the highly specific recognition and reactivity
properties of small molecules to probe functional rela-
tionships. For example, with the revelation that the di-
versity of functional human proteins far exceeds the
number of transcribed genes, scientists now have the
daunting challenge of identifying, cataloging, and un-
derstanding the functional significance of a bevy of
posttranslational modifications. Although some of these
modifications, most notably phosphorylation, can be
assessed by traditional biochemical techniques, chem-
ical biologists have stepped up to the task of exploring
more complex posttranslational modifications. Glyco-
sylation may be the most chemically complex type of
posttranslation modification, possessing both variable
linkages and variable monosaccharide building blocks.
Found on over 50% of all proteins [1], glycans are im-
portant for mediating protein stability, conformation,
and catalytic activity and are absolutely critical for in-
tercellular communication. The ability to identify and
manipulate glycosylation sites is a central focus of the
Bertozzi Laboratory (UC Berkeley). Dr. Carolyn Bertozzi
explained that the study of O-linked glycosylation has
been hindered by the lack of small-molecule inhibitors
or affinity reagents for the glycosyltransferases (ppGal-
NacT) that install the initial N-acetyl galactosamine
residue onto polypeptide substrates [2]. The Bertozzi
Lab used a high-throughput screen to identify uridine-
sugar conjugates that inhibit the activity of all 20 human
isoforms of ppGalNAcT but are inactive against other
cellular glycosyltransferases and nucleotide-utilizing
enzymes [3]. These new inhibitors can be used to de-
termine whether a particular protein is being glycosy-*Correspondence: joshua.kritzer@gmail.com (J.A.K.); nathan_
luedtke@yahoo.com (N.W.L.)lated by a ppGalNAcT and to assess the effects of spe-
cific O-linked glycosylation. In a related endeavor, Dr.
Bertozzi described the selective inhibition or activation
of a single glucosyltransferase isoform by genetically
splitting the enzyme into two functional domains and
fusing each to a rapamycin-mediated heterodimeriza-
tion domain (FKBP or FRB) [4]. The glycosyltransfer-
ase is reassembled in living cells upon addition of
rapamycin, thus reactivating its catalytic activity [5].
This simple “on switch” can be applied to other en-
zymes, including sulfotransferases, and is currently be-
ing tested in model organisms.
In addition to providing new tools for deciphering
protein modification and activity, one of the primary
goals of chemical biology is to track the movements,
actions, and interactions of biomolecules in their native
context. Dr. Bertozzi explained how azide-modified
monosaccharides can be incorporated into cell-surface
proteoglycans in cell culture and in mice. A modified
version of the Staudinger reaction is then used to cova-
lently link the azide-modified cell-surface proteoglycan
to a phosphine-containing imaging or capture reagent
[6]. Amazingly, this Staudinger ligation can be per-
formed in live mice with chemical yields of approxi-
mately 60% [7]. Future studies in the Bertozzi lab will
move toward direct imaging of live animals by using
proteoglycans modified with PET and NMR probes.
Although Dr. Bertozzi’s methods take advantage of
cellular metabolic pathways to introduce site-specific
tags at glycosylation sites, the tagging and tracking of
most proteins typically necessitates genetically fusing
large proteins or short peptides to the protein of inter-
est, often as recognition modules for small-molecule
probes [8]. This approach is effective but has its disad-
vantages, most notably perturbation of protein function
by the added domain or imperfect site specificity of the
small-molecule probe. Dr. Alice Ting’s laboratory (MIT)
has been at the forefront of developing new techniques
for tracking proteins in live cells. In her talk, Dr. Ting
described a new strategy that involves genetically
adding a 15-residue biotin acceptor peptide (AP) to a
eukaryotic protein of interest [9]. The AP sequence is
then biotinylated by the E. coli biotin ligase BirA with
exceptional site specificity because BirA is function-
ally orthogonal to mammalian biotin ligases. Dr. Ting’s
method allows rapid, specific, and robust biotinylation
of virtually any cell-surface protein in minutes, and use
of a streptavidin-linked quantum dot probe allows
tagged proteins to be monitored for hours without deg-
radation of the signal because of dissociation or photo-
bleaching. With the precision and speed of an enzy-
matic modification to provide extraordinary specificity,
Dr. Ting’s method is an ingenious twist on in vivo pro-
tein tagging.
In a striking demonstration of the new technique, Dr.
Ting showed a movie clip tracking the movement of
individual AMPA receptors along a neuron’s surface, al-
lowing direct observation that some AMPA receptors
are highly mobile while others remain stationary [10].
She also discussed pulse-chase experiments carried
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tdin labeling before and after stimulation of neuronal
surface remodeling. The labeling was performed with a i
rgreen organic dye before stimulation and with red
quantum dots afterward, leading to a dual-color as- s
say for turnover of AMPA receptor subunits that could
be monitored in real time. Overall, the elegance of c
fDr. Ting’s method, along with the striking visuals the
method produces, should make it a critical tool for cell b
lbiologists interested in tracking cell-surface proteins.
A major theme of the Yale Chemical Biology Sympo- a
psium was the application of chemical biology to drug
discovery. Dr. Peter Lansbury’s work has epitomized t
bthe creative application of chemistry to the biology of
devastating human diseases, illustrating how “applied 5
schemical biology” may be the most promising route to
discovering new therapies. In his talk, Dr. Lansbury de- u
wscribed mutagenesis experiments on superoxide dis-
mutase 1 (SOD1), a protein whose misfolding and ag- f
bgregation is implicated in the pathology of amyotrophic
lateral sclerosis (ALS) [11]. His group found that muta- “
itions that fill a cavity in the SOD1 dimerization interface
stabilize the dimeric form of SOD1 and prevent misfold- c
aing. This presented the intriguing possibility that small
drug-like molecules that bind in this cavity could also c
fprevent protein misfolding. Keenly focused on getting
drug candidates into the clinic as soon as possible, Dr. d
cLansbury’s group performed an in silico docking screen
of a library of existing drugs, looking for molecules that n
ddocked into the dimerization interface. Of 100 pre-
dicted hits, 15 were shown to stabilize the dimeric form i
nof SOD1 and prevent SOD1 aggregation [12]. These
candidates are currently being optimized for potency t
eand selectivity.
Dr. Lansbury’s presentation also updated us on his c
ccurrent efforts targeting Parkinson’s disease (PD) by
following up on his initial report of small molecules that s
starget ubiquitin-C-hydrolase L1 (UCH-L1) [13]. UCH-L1
is found in high levels in the brain, and it has been
dlinked to PD by virtue of an unexpected dimerization-
dependent ubiquitin ligase activity [14]. Dr. Lansbury d
poutlined a potential mechanism for UCH-L1 action by
showing that UCH-L1 is farnesylated and membrane t
danchored in both mammalian tissues and cultured
cells. He hypothesized that farnesylation and subse- c
mquent membrane localization of UCH-L1 triggers its di-
merization and ubiquitin-ligase activity. Among the evi- c
idence presented, perhaps the most compelling was
that farnesyltransferase inhibitors prevent the death of t
vdopaminergic neurons in cell-culture models of PD. In
validating UCH-L1 as a drug target, Dr. Lansbury has d
aprovided ammunition for those who, like Lansbury him-
self, are willing to attack PD at the molecular level. s
hTarget validation is perhaps the greatest hurdle in de-
veloping new drugs, as the keynote speaker, Dr. Joshua q
tBoger (Chairman, President, and CEO of Vertex Phar-
maceuticals, Inc.), reminded the audience. Vertex’s R
Nhighly successful strategy for drug discovery begins
with a validated protein target and integrates structural c
ebiology, computational design, and medicinal chemis-
try to engineer a small-molecule drug. As a case study, t
iDr. Boger described the development of VX-680, a spe-
cific Aurora kinase inhibitor currently in phase I clinical s
atrials for patients with solid tumors. Dr. Boger allowedhat kinase active sites are quite similar, but insisted
hat specific inhibition of kinases by small molecules
s “not a lemonade-from-lemons proposition.” It simply
equires precise tailoring of small molecules to fit a
tructurally distinct portion of the target kinase.
Vertex’s approach consists of an iterative design pro-
ess with well-chosen small-molecule scaffolds. In the
irst stage, high-throughput screening of a scaffold li-
rary against the target typically yields weak hits as
ead compounds. Even at this early stage, Vertex evalu-
tes the pharmacokinetics of initial hits to judge their
otential as drugs. High-throughput crystallography is
hen used to decipher how the scaffold fits into the ATP
inding pocket of the enzyme. Vertex has generated
0–100 kinase•inhibitor crystal structures per year
ince 1999. Potential variants of each scaffold are eval-
ated with a rapid computational docking algorithm,
hich winnows the pool of possible lead derivatives
rom nearly 1012 to several thousand; these can then
e evaluated experimentally. Dr. Boger admitted that
affinity is the easy part,” implying that once Vertex
dentifies a promising scaffold, the design and testing
ycle (termed “morphing”) reliably turns out a high-
ffinity ligand for the desired target. During this pro-
ess, the experimental data for all drug targets, scaf-
olds, and derivatives are maintained in an integrated
atabase. This promotes “target hopping,” which oc-
urs when a scaffold originally developed for one ki-
ase is adapted for another based on clues from the
atabase. Throughout his talk, Dr. Boger stressed the
mportance of obtaining high quality data on both ki-
ase specificity and pharmacokinetics so that only
hose candidates with high potency and minimal side
ffects are advanced into clinical trials. Dr. Boger con-
luded by predicting that in the future, cancers will be
lassified not by their tissue of origin or their aggres-
iveness but by their responses to potent and specific
mall molecules.
Vertex has been a pioneer in structure-based drug
esign, demonstrating the cumulative power of hun-
reds of crystal structures of target•inhibitor com-
lexes and rapid docking algorithms. Although such
echniques have become a staple of modern drug
esign, static snapshots and rigid docking exercises
annot fully describe the functions of complex bio-
olecules or their responses to binding events. Thus,
haracterizing the dynamic motions of biomolecules
s essential to understanding fundamental aspects of
heir function. Dr. Patrick Loria’s laboratory (Yale Uni-
ersity) uses advanced NMR techniques and site-
irected mutagenesis to examine the relationships
mong enzyme motion, substrate binding, and cataly-
is. The backbone motions of RNase A bound to the
igh-affinity substrate mimic “pTppAp” were recently
uantified with NMR spin-relaxation measurements in
he Loria Lab. Interestingly, backbone motions within
Nase A are not altered upon pTppAp binding, and the
MR data demonstrated that, rather than causing a
onformational change, ligand binding alters an already
xisting equilibrium between two discrete conforma-
ions of RNase A [15]. This result contrasts with ligand-
nduced conformation changes often observed in other
ystems and may represent a general feature of high-
ffinity substrate binding and enzyme inhibition. In a
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the motions of a molecular “hinge” region of triose-
phosphate isomerase (TIM) that opens and closes the
active site can affect substrate binding and catalytic
turnover. Mutations of residues at the hinge that join
the loop region to the rest of the enzyme modestly alter
substrate binding but dramatically increase molecular
motions in the hinge region for both the apo and sub-
strate bound forms of the enzyme. This flexibility allows
access to nonproductive conformations, leading to a
profound loss in catalytic activity. Dr. Loria concluded
that although the dynamic opening and closing of en-
zyme active sites is essential for catalysis, hinge-like
motions are sufficiently well-defined so that too much
flexibility abolishes catalytic activity.
Proteins are not the only biomolecules whose func-
tions cannot be fully understood with static pictures.
The dynamics and flexibility of RNA are critical for its
ability to mediate both information storage and chemi-
cal catalysis. Given scenarios involving a prebiotic
“RNA world” in which RNA served as the evolutionary
precursor to metabolic proteins, one might expect RNA
to have evolved regulatory binding sites for simple me-
tabolites. Dr. Ron Breaker (Yale University) gave an
account of the discovery and exploration of “ribo-
switches,” RNA motifs that rely on propagation of con-
formational changes to control gene expression [16].
The journey began with in vitro selection experiments
showing that the activity of a self-cleaving RNA enzyme
can be allosterically regulated by small molecule bind-
ing [17]. Dr. Breaker explained how such sophisticated
RNA function led to speculation that natural systems
might utilize RNA•small-molecule binding interactions
to control gene expression. A search of the literature re-
vealed a number of well-characterized prokaryotic genes
that were regulated through product feedback but
lacked an identified protein modulator. Suspected ri-
boswitches were identified as highly conserved se-
quences in the 5# untranslated regions of these genes
and were subsequently assessed for metabolite bind-
ing by inline probing, a method that relies on differential
rates of phosphodiester bond scission in structured
versus unstructured regions of RNA [18]. These experi-
ments showed that certain regions within the suspect-
ed riboswitches exhibit changes in RNA flexibility and
geometry upon addition of the metabolite, revealing a
binding event at these sites. The resulting RNA•small-
molecule complexes modulate gene expression by nu-
merous mechanisms at the level of either transcription
or translation [19]. Riboswitches can even exhibit coop-
erative substrate binding that leads to highly sensitive
transcriptional control [20]. Currently, there are 11 dif-
ferent classes of known riboswitches controlling per-
haps 2% of all gene expression in B. subtilis. No
evidence has yet been found for the presence of ribo-
switches in higher-order organisms, which led Dr.
Breaker to see prokaryotic riboswitches as targets for
new antibiotics. The Breaker group used a newly re-
ported crystal structure of the guanine riboswitch [21]
to rationally design guanine derivatives that exhibit
promising antibiotic activity. Combined with the recent
insights into how aminoglycoside antibiotics selectively
bind to and inhibit prokaryotic ribosomal RNA, the dis-covery of riboswitches has demonstrated that RNA is
an important and underutilized drug target.
Conclusions
The 2005 Yale Chemical Biology Symposium made it
clear that chemical biology’s reach is expanding into
a wide variety of fields. In areas as diverse as drug
discovery, neurochemistry, and molecular genetics,
small-molecule-based approaches are becoming the
methods of choice for careful profiling and specific ma-
nipulation of biological processes. In both industry and
academia, chemical biology has provided indispens-
able tools that can address even the most complex
challenges in biology and human disease.
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